A Phase 2 interventional study of FE 999049 and Gonal - F in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 8 sites in 4 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2020-11-17.
Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 2, and was the 1st registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 37 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 265 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 11th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2011, is one of 6 in phase 2, and was the 15th registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FE 999049
Drug: FE 999049
Drug: FE 999049
Drug: FE 999049
Drug: FE 999049
Drug: Gonal - F
Number of Oocytes Retrieved
Time frame: Day of oocyte retrieval (up to Day 18 after start of stimulation)
Number and Size of Follicles During Stimulation
Follicular volume at end of stimulation
Time frame: End of stimulation (up to 16 stimulation days)
Endocrine Profile
Estradiol at end of stimulation
Time frame: End of stimulation (up to 16 stimulation days)
Total IMP Dose
Time frame: End of stimulation (up to 16 stimulation days)
Number of Fertilised Oocytes
An oocyte with 2 pronuclei was regarded as correctly fertilised
Time frame: Day 1 after insemination
Number and Quality of Blastocysts on Day 5
Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher
Time frame: Day 5 after oocyte retrieval
Clinical Pregnancy With Fetal Heart Beat Rate
Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat
Time frame: 5-6 weeks after transfer
Frequency and Intensity of Adverse Events
Time frame: From signing informed consent form until end of trial visit (up to 5 months)
A total of 7 sites randomised subjects to the trial: 1 in Belgium, 1 in Czech Republic, 1 in Denmark and 4 in Spain.
| Milestone | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Started | 42 | 45 | 44 | 44 | 47 | 43 |
| Completed | 39 | 39 | 42 | 44 | 43 | 42 |
| Not completed | 3 | 6 | 2 | 0 | 4 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Did not attend scheduled visit | 1 | 4 | 0 | 0 | 2 | 1 |
| Withdrew: Poor response | 2 | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Personal reasons | 0 | 0 | 0 | 0 | 1 | 0 |
| Oocytes | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Number of Oocytes Retrieved | 5.2 ± 3.3 | 7.9 ± 5.9 | 9.2 ± 4.6 | 10.5 ± 7.0 | 12.2 ± 5.9 | 10.4 ± 5.2 |
Follicular volume at end of stimulation
| cm^3 | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Number and Size of Follicles During Stimulation | 19.2 ± 7.0 | 23.0 ± 10.5 | 25.0 ± 9.2 | 27.9 ± 15.6 | 28.2 ± 9.5 | 26.7 ± 9.2 |
Estradiol at end of stimulation
| pmol/L | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Endocrine Profile | 3641.9 ± 2954.6 | 5221.1 ± 3378.8 | 5689.5 ± 3995.7 | 6171.8 ± 3855.9 | 6442.0 ± 3195.2 | 5750.7 ± 3709.7 |
| µg | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Total IMP Dose | 50.0 ± 11.6 | 61.9 ± 13.7 | 71.9 ± 14.1 | 81.0 ± 14.2 | 97.8 ± 22.0 | 94.7 ± 18.1 |
An oocyte with 2 pronuclei was regarded as correctly fertilised
| Fertilised oocytes | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Number of Fertilised Oocytes | 3.7 ± 2.5 | 5.4 ± 3.8 | 4.9 ± 2.7 | 6.1 ± 5.1 | 6.7 ± 3.5 | 6.4 ± 3.5 |
Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher
| Blastocysts | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Total blastocysts | 2.3 ± 1.7 | 3.1 ± 2.7 | 2.7 ± 2.0 | 2.8 ± 2.8 | 3.2 ± 2.2 | 3.5 ± 2.5 |
| Good quality blastocysts | 0.9 ± 1.2 | 1.4 ± 1.7 | 1.2 ± 1.2 | 1.4 ± 1.5 | 1.3 ± 1.3 | 1.6 ± 1.6 |
Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat
| percentage | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Clinical Pregnancy With Fetal Heart Beat Rate | 36 (21.6 to 52.0) | 40 (25.7 to 55.7) | 36 (22.4 to 52.2) | 25 (13.2 to 40.3) | 40 (26.4 to 55.7) | 51 (35.5 to 66.7) |
| participants | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Any mild adverse events | 15 | 17 | 17 | 18 | 15 | 11 |
| Any moderate adverse events | 2 | 6 | 5 | 9 | 8 | 2 |
| Any severe adverse events | 0 | 0 | 0 | 1 | 0 | 0 |
Collected over From signing informed consent form until the end of trial visit (up to 5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 5.2 µg | 0/42 (0%) | 0/42 (0%) | 11/42 (26.2%) |
| FE 999049 6.9 µg | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| FE 999049 8.6 µg | 0/44 (0%) | 0/44 (0%) | 11/44 (25%) |
| FE 999049 10.3 µg | 0/44 (0%) | 1/44 (2.3%) | 12/44 (27.3%) |
| FE 999049 12.1 µg | 0/47 (0%) | 0/47 (0%) | 11/47 (23.4%) |
| GONAL-F 11 µg | 0/43 (0%) | 0/43 (0%) | 4/43 (9.3%) |
| Event | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/42 | 0/45 | 0/44 | 1/44 | 0/47 | 0/43 |
| Event | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/42 | 4/45 | 5/44 | 3/44 | 1/47 | 1/43 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 3/42 | 5/45 | 2/44 | 5/44 | 5/47 | 1/43 |
| Vaginal haemorrhageReproductive system and breast disorders | 2/42 | 1/45 | 4/44 | 3/44 | 2/47 | 1/43 |
| NauseaGastrointestinal disorders | 2/42 | 0/45 | 0/44 | 1/44 | 4/47 | 0/43 |
| Pelvic painReproductive system and breast disorders | 2/42 | 0/45 | 1/44 | 3/44 | 2/47 | 2/43 |
| Age, Continuous(years) | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33.6 ± 2.24 | 32.3 ± 3.51 | 32.8 ± 2.44 | 32.3 ± 3.21 | 32.6 ± 2.97 | 32.4 ± 3.04 | 32.7 ± 2.95 |
| Sex: Female, Male(Participants) | FE 999049 5.2 µg | FE 999049 6.9 µg | FE 999049 8.6 µg | FE 999049 10.3 µg | FE 999049 12.1 µg | GONAL-F 11 µg | Total |
|---|---|---|---|---|---|---|---|
| Female | 42 | 45 | 44 | 44 | 47 | 43 | 265 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Sep 2011, a primary completion of Apr 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 6 years 4 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta